Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
NCT06011889

Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome

Led by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · Updated on 2026-04-13

60

Participants Needed

1

Research Sites

215 weeks

Total Duration

On this page

Sponsors

N

National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland

Lead Sponsor

M

Medical Research Agency, Poland

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study includes adult patients with SAPHO syndrome (ORPHA: 793), meeting the modified classification criteria according to Kahn (2003), with the ineffectiveness of standard treatment (patient's global assessment of the disease on the VAS scale greater than or equal to 4 cm with accompanying pain on the VAS scale greater than or equal to 4 cm) treated with non-steroidal anti-inflammatory drugs in a stable dose for at least 4 weeks and/or classical disease-modifying antirheumatic drugs in stable doses for at least 12 weeks.

CONDITIONS

Official Title

Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of SAPHO syndrome according to modified Kahn criteria from 2003
  • Age over 18 years
  • Patient overall disease and pain assessment on VAS both 64; 4 cm
  • Providing informed consent to participate in the study
Not Eligible

You will not qualify if you...

  • Contraindications according to the Summary of Product Characteristics for Enbrel
  • Pregnancy, breastfeeding, or inability to use effective contraception during the study
  • Change in NSAIDs dose in the last 4 weeks
  • Dose modification of DMARDs in the last 12 weeks
  • Use of biological or synthetic targeted drugs in the last 12 weeks
  • Use of corticosteroids (oral or local), bisphosphonates, or antibiotics in the last 4 weeks
  • Any medical condition that contraindicates etanercept treatment as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Centrum Wsparcia Badań Klinicznych

Warsaw, Masovian Voivodeship, Poland, 02-637

Actively Recruiting

Loading map...

Research Team

J

Jakub Wroński, PhD, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here